178 related articles for article (PubMed ID: 29350258)
1. Antitumor effects of radionuclide treatment using α-emitting meta-
Ohshima Y; Sudo H; Watanabe S; Nagatsu K; Tsuji AB; Sakashita T; Ito YM; Yoshinaga K; Higashi T; Ishioka NS
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):999-1010. PubMed ID: 29350258
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects and potential therapeutic response biomarkers in α-emitting
Ohshima Y; Kono N; Yokota Y; Watanabe S; Sasaki I; Ishioka NS; Sakashita T; Arakawa K
Theranostics; 2019; 9(6):1538-1549. PubMed ID: 31037122
[TBL] [Abstract][Full Text] [Related]
3. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[
Ohshima Y; Sasaki I; Watanabe S; Sakashita T; Higashi T; Ishioka NS
Nucl Med Biol; 2022; 112-113():44-51. PubMed ID: 35802985
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
5. Manual on the proper use of meta-[
Ukon N; Higashi T; Hosono M; Kinuya S; Yamada T; Yanagida S; Namba M; Nakamura Y
Ann Nucl Med; 2022 Aug; 36(8):695-709. PubMed ID: 35794455
[TBL] [Abstract][Full Text] [Related]
6. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
7. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Cunningham SH; Mairs RJ; Wheldon TE; Welsh PC; Vaidyanathan G; Zalutsky MR
Br J Cancer; 1998 Jun; 77(12):2061-8. PubMed ID: 9649115
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
Nucl Med Biol; 1996 Aug; 23(6):851-6. PubMed ID: 8940730
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
10. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
Vaidyanathan G; Strickland DK; Zalutsky MR
Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent
Sudo H; Tsuji AB; Sugyo A; Nagatsu K; Minegishi K; Ishioka NS; Ito H; Yoshinaga K; Higashi T
Transl Oncol; 2019 Jul; 12(7):879-888. PubMed ID: 31078058
[TBL] [Abstract][Full Text] [Related]
12. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
13. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
14. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
Vaidyanathan G; Zalutsky MR
Bioconjug Chem; 1992; 3(6):499-503. PubMed ID: 1463779
[TBL] [Abstract][Full Text] [Related]
15. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
16. Human dosimetry of free
Ukon N; Zhao S; Washiyama K; Oriuchi N; Tan C; Shimoyama S; Aoki M; Kubo H; Takahashi K; Ito H
EJNMMI Phys; 2020 Sep; 7(1):58. PubMed ID: 32960387
[TBL] [Abstract][Full Text] [Related]
17. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
[TBL] [Abstract][Full Text] [Related]
18. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
19. Absorbed dose simulation of meta-
Sakashita T; Watanabe S; Hanaoka H; Ohshima Y; Ikoma Y; Ukon N; Sasaki I; Higashi T; Higuchi T; Tsushima Y; Ishioka NS
Ann Nucl Med; 2021 Jan; 35(1):121-131. PubMed ID: 33222123
[TBL] [Abstract][Full Text] [Related]
20. A kit method for the high level synthesis of [211At]MABG.
Vaidyanathan G; Affleck DJ; Alston KL; Zhao XG; Hens M; Hunter DH; Babich J; Zalutsky MR
Bioorg Med Chem; 2007 May; 15(10):3430-6. PubMed ID: 17387017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]